Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies.

Reference

Jones TM, Espitia C, Wang W, Nawrocki ST, Carew JS. 2019. Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies. Cancer Commun (Lond). 39:72. doi:10.1186/s40880-019-0418-0.